The 2026 European Association of Urology (EAU) annual meeting featured an advancements in metastatic castration resistant prostate cancer (mCRPC) therapy session and a presentation by Dr. Giulio ...

A meta-analysis explores whether there’s a survival benefit to adding hormone therapy to postoperative radiation for patients with low PSA levels.

The Bellmunt Risk Score can provide prognostic information on survival among patients with metastatic castration-resistant prostate cancer, new data suggest.

In oligometastatic castration-resistant prostate cancer, the rationale to use local SBRT is improved disease control.

Using de-identified data from the National Cancer Institute, researchers followed 205 patients—average age, 61 years—with prostate cancer and preexisting depression. Patients with both conditions had ...

A personalized peptide vaccine slashed prostate-specific antigen levels by as much as 99.6% in some men with advanced prostate cancer, according to a phase II clinical trial conducted at Kurume ...

Add Yahoo as a preferred source to see more of our stories on Google. If a person has an "aggressive" prostate cancer with a Gleason score of 9, what does that mean? What's the outlook when it comes ...

The addition of hormone therapy to radiotherapy improves overall survival in men with high-risk prostate cancer, over ...

In prostate cancer, prostate brachytherapy boost improves biochemical failure at 10 years but does not prolong long-term OS compared to EBRT boost.

About 60% of low‑risk prostate cancer patients are opting for active surveillance — and long‑term survival remains high.

Staging means finding out how far prostate cancer has spread in your body. Physicians group prostate cancers into stages I (1) through IV (4), with stage I being the least advanced and stage IV being ...

The FDA's cancer advisors will discuss AstraZeneca’s application for the oral SERD camizestrant in breast cancer and the AKT ...